Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36396045)

  • 1. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance.
    Hu HF; Gao GB; He X; Li YY; Li YJ; Li B; Pan Y; Wang Y; He QY
    J Adv Res; 2023 Sep; 51():135-147. PubMed ID: 36396045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission.
    Hu HF; Xu WW; Li YJ; He Y; Zhang WX; Liao L; Zhang QH; Han L; Yin XF; Zhao XX; Pan YL; Li B; He QY
    Theranostics; 2021; 11(4):1828-1844. PubMed ID: 33408784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
    Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
    Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
    Xie X; Tang SC; Cai Y; Pi W; Deng L; Wu G; Chavanieu A; Teng Y
    Oncotarget; 2016 Sep; 7(36):58111-58120. PubMed ID: 27517156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
    Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of the N terminus of ADP-ribosylation factor with the PH domain of the GTPase-activating protein ASAP1 requires phosphatidylinositol 4,5-bisphosphate.
    Roy NS; Jian X; Soubias O; Zhai P; Hall JR; Dagher JN; Coussens NP; Jenkins LM; Luo R; Akpan IO; Hall MD; Byrd RA; Yohe ME; Randazzo PA
    J Biol Chem; 2019 Nov; 294(46):17354-17370. PubMed ID: 31591270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of DNAJB6 promotes colorectal cancer cell invasion through an IQGAP1/ERK-dependent signaling pathway.
    Zhang TT; Jiang YY; Shang L; Shi ZZ; Liang JW; Wang Z; Zhang Y; Hao JJ; Jia XM; Xu X; Cai Y; Zhan QM; Wang MR
    Mol Carcinog; 2015 Oct; 54(10):1205-13. PubMed ID: 25044025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR‑124 inhibits cell growth through targeting IQGAP1 in colorectal cancer.
    Fan J; Zhang W; Wu Y; Wan P; Guo Q; Zhang Y
    Mol Med Rep; 2018 Dec; 18(6):5270-5278. PubMed ID: 30272357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer.
    Schlienger S; Campbell S; Pasquin S; Gaboury L; Claing A
    Oncotarget; 2016 Mar; 7(13):15811-27. PubMed ID: 26908458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plastin 1 drives metastasis of colorectal cancer through the IQGAP1/Rac1/ERK pathway.
    Zhang T; Wang Z; Liu Y; Huo Y; Liu H; Xu C; Mao R; Zhu Y; Liu L; Wei D; Liu G; Pan B; Tang Y; Zhou Z; Yang C; Guo Y
    Cancer Sci; 2020 Aug; 111(8):2861-2871. PubMed ID: 32350953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells.
    Lewis-Saravalli S; Campbell S; Claing A
    Cell Signal; 2013 Sep; 25(9):1813-9. PubMed ID: 23707487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of molecular anti-metastasis mechanisms of lycorine in colorectal cancer by RNA-seq analysis.
    Gao L; Feng Y; Ge C; Xu X; Wang S; Li X; Zhang K; Wang C; Dai F; Xie S
    Phytomedicine; 2021 May; 85():153530. PubMed ID: 33761445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.
    Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA
    Nat Med; 2013 May; 19(5):626-630. PubMed ID: 23603816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.
    Tran KB; Kolekar S; Wang Q; Shih JH; Buchanan CM; Deva S; Shepherd PR
    Mol Cancer Ther; 2022 Dec; 21(12):1777-1787. PubMed ID: 36198029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The amino terminus of ADP-ribosylation factor (ARF) 1 is essential for interaction with Gs and ARF GTPase-activating protein.
    Randazzo PA; Terui T; Sturch S; Kahn RA
    J Biol Chem; 1994 Nov; 269(47):29490-4. PubMed ID: 7961931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
    Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
    J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib downmodulates aggressiveness mediators of colorectal cancer (CRC): Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP), Protein Tyrosine Phosphatase 1B (PTP1B) and Transforming Growth Factor β (TGFβ).
    Cordeiro HG; de Sousa Faria AV; Ferreira-Halder CV
    Biol Chem; 2020 Aug; 401(9):1063-1069. PubMed ID: 32229687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.